About
Small Molecules
Areas of Focus
Categories
Small Molecule PharmaceuticalNJ, NY, PA
Team (22)
Adrienne Clements-Egan, Ph.D.
Larimar Therapeutics
team_member
Carole Ben-Maimon, MD
Larimar Therapeutics
team_member
Francis Michael Conway, CPA
Larimar Therapeutics
team_member
Frank E. Thomas
Larimar Therapeutics
team_member
Frank Nazzario, RPh
Larimar Therapeutics
team_member
Giovanni Manfredi, MD, PhD
Larimar Therapeutics
team_member
Clinical Trials (7)
View allTotal Trials
7
As Lead Sponsor
7
As Collaborator
0
Total Enrollment
268
By Phase
PHASE1: 3PHASE2: 2
By Status
COMPLETED: 5RECRUITING: 1ENROLLING_BY_INVITATION: 1
Clinical Trials Pipeline7 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT06681766Lead Sponsor
A Study to Assess Nomlabofusp in Adolescents and Children with Friedreich's Ataxia
PHASE1Recruiting
30 participants
Started: Dec 6, 2024 · Completed: Aug 31, 2025
NCT06447025Lead Sponsor
An Open Label Extension Study of CTI-1601 in Subjects With Friedreich's Ataxia
PHASE2Enrolling by invitation
75 participants
Started: Jan 25, 2024 · Completed: Jan 31, 2027
NCT05579691Lead Sponsor
A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's Ataxia
PHASE2Completed
28 participants
Started: Sep 21, 2022 · Completed: Dec 4, 2023
NCT05028764Lead Sponsor
Determine Range of Tissue Frataxin Concentrations and Other Potential Biomarkers
N/ACompleted
60 participants
Started: Aug 4, 2021 · Completed: Feb 4, 2022
NCT04519567Lead Sponsor
Multiple Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia
PHASE1Completed
27 participants
Started: Jul 31, 2020 · Completed: Mar 16, 2021
Locations (1)
Headquarters
Bala Cynwyd, PA, United States
Map
Loading map...